Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial

BACKGROUND: Malignant peritoneal mesothelioma (MPM) is an aggressive malignancy with a poor prognosis. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival outcomes, but recurrence rates remain high. Dendritic cell-based immunotherapy (DCBI) showed prom...

Descripción completa

Detalles Bibliográficos
Autores principales: Dietz, Michelle V, Quintelier, Katrien L A, van Kooten, Job P, de Boer, Nadine L, Vink, Madelief, Brandt-Kerkhof, Alexandra R M, Verhoef, Cornelis, Saeys, Yvan, Aerts, Joachim G J V, Willemsen, Marcella, Van Gassen, Sofie, Madsen, Eva V E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401259/
https://www.ncbi.nlm.nih.gov/pubmed/37536940
http://dx.doi.org/10.1136/jitc-2023-007070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401259/
https://www.ncbi.nlm.nih.gov/pubmed/37536940
http://dx.doi.org/10.1136/jitc-2023-007070

Ejemplares similares